MedTrace Logo

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

NCT02295722 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-07-08

No results posted yet for this study

Summary

Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell transplantation in patients with relapsed/refractory lymphoma.

Conditions

  • Hodgkin's Lymphoma - Relapsed/Refractory
  • Non-Hodgkin's Lymphoma - Aggressive
  • Follicular Lymphoma

Interventions

DRUG

Gemcitabine

gemcitabine 1.5 g/m2 INFUSED

DRUG

Melphalan

200 mg/m2

OTHER

ASCT

Day 0 - Stem cell infusion

Sponsors & Collaborators

  • Tom Baker Cancer Centre

    collaborator OTHER

  • AHS Cancer Control Alberta

    lead OTHER

Principal Investigators

  • MONA SHAFEY, MD · Tom Baker Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2023-02-28
Completion
2023-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02295722 on ClinicalTrials.gov